Intrinsic value of C.R. Bard - BCR

Previous Close

$315.98

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$315.98

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of BCR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 22.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  8.72
  11.00
  10.40
  9.86
  9.37
  8.94
  8.54
  8.19
  7.87
  7.58
  7.32
  7.09
  6.88
  6.69
  6.53
  6.37
  6.24
  6.11
  6.00
  5.90
  5.81
  5.73
  5.66
  5.59
  5.53
  5.48
  5.43
  5.39
  5.35
  5.31
  5.28
Revenue, $m
  3,714
  4,123
  4,551
  5,000
  5,469
  5,957
  6,466
  6,996
  7,546
  8,119
  8,713
  9,331
  9,974
  10,641
  11,336
  12,058
  12,810
  13,593
  14,408
  15,259
  16,145
  17,070
  18,036
  19,044
  20,098
  21,199
  22,350
  23,554
  24,814
  26,133
  27,513
Variable operating expenses, $m
 
  3,630
  3,995
  4,376
  4,775
  5,190
  5,623
  6,073
  6,541
  7,027
  7,533
  7,932
  8,478
  9,046
  9,636
  10,250
  10,889
  11,555
  12,248
  12,971
  13,724
  14,511
  15,331
  16,188
  17,084
  18,020
  18,999
  20,022
  21,093
  22,214
  23,387
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,008
  3,630
  3,995
  4,376
  4,775
  5,190
  5,623
  6,073
  6,541
  7,027
  7,533
  7,932
  8,478
  9,046
  9,636
  10,250
  10,889
  11,555
  12,248
  12,971
  13,724
  14,511
  15,331
  16,188
  17,084
  18,020
  18,999
  20,022
  21,093
  22,214
  23,387
Operating income, $m
  707
  492
  556
  624
  694
  767
  844
  923
  1,006
  1,091
  1,180
  1,399
  1,496
  1,596
  1,700
  1,808
  1,921
  2,038
  2,161
  2,288
  2,421
  2,560
  2,705
  2,856
  3,014
  3,179
  3,351
  3,532
  3,721
  3,919
  4,126
EBITDA, $m
  920
  749
  827
  908
  994
  1,082
  1,175
  1,271
  1,371
  1,475
  1,583
  1,695
  1,812
  1,933
  2,060
  2,191
  2,327
  2,470
  2,618
  2,772
  2,933
  3,101
  3,277
  3,460
  3,651
  3,851
  4,061
  4,279
  4,508
  4,748
  4,999
Interest expense (income), $m
  50
  57
  71
  86
  101
  117
  134
  152
  170
  189
  208
  228
  250
  272
  294
  318
  343
  369
  395
  423
  452
  483
  514
  547
  582
  618
  656
  695
  736
  779
  824
Earnings before tax, $m
  664
  435
  485
  538
  593
  650
  709
  771
  836
  903
  972
  1,171
  1,246
  1,324
  1,405
  1,490
  1,578
  1,670
  1,765
  1,865
  1,969
  2,077
  2,190
  2,308
  2,432
  2,561
  2,696
  2,837
  2,985
  3,139
  3,301
Tax expense, $m
  133
  117
  131
  145
  160
  175
  192
  208
  226
  244
  263
  316
  336
  358
  379
  402
  426
  451
  477
  503
  532
  561
  591
  623
  657
  691
  728
  766
  806
  848
  891
Net income, $m
  531
  317
  354
  392
  433
  474
  518
  563
  610
  659
  710
  855
  910
  967
  1,026
  1,088
  1,152
  1,219
  1,289
  1,361
  1,437
  1,516
  1,599
  1,685
  1,775
  1,869
  1,968
  2,071
  2,179
  2,292
  2,410

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  905
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  5,306
  4,885
  5,393
  5,924
  6,480
  7,059
  7,662
  8,289
  8,941
  9,619
  10,324
  11,056
  11,817
  12,608
  13,431
  14,287
  15,178
  16,105
  17,072
  18,079
  19,129
  20,225
  21,369
  22,564
  23,812
  25,117
  26,481
  27,908
  29,401
  30,963
  32,599
Adjusted assets (=assets-cash), $m
  4,401
  4,885
  5,393
  5,924
  6,480
  7,059
  7,662
  8,289
  8,941
  9,619
  10,324
  11,056
  11,817
  12,608
  13,431
  14,287
  15,178
  16,105
  17,072
  18,079
  19,129
  20,225
  21,369
  22,564
  23,812
  25,117
  26,481
  27,908
  29,401
  30,963
  32,599
Revenue / Adjusted assets
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
  0.844
Average production assets, $m
  1,496
  1,661
  1,834
  2,015
  2,204
  2,401
  2,606
  2,819
  3,041
  3,272
  3,511
  3,761
  4,019
  4,288
  4,568
  4,859
  5,162
  5,478
  5,807
  6,149
  6,507
  6,879
  7,268
  7,675
  8,099
  8,543
  9,007
  9,492
  10,000
  10,531
  11,088
Working capital, $m
  1,207
  334
  369
  405
  443
  483
  524
  567
  611
  658
  706
  756
  808
  862
  918
  977
  1,038
  1,101
  1,167
  1,236
  1,308
  1,383
  1,461
  1,543
  1,628
  1,717
  1,810
  1,908
  2,010
  2,117
  2,229
Total debt, $m
  1,642
  2,041
  2,460
  2,898
  3,357
  3,834
  4,332
  4,849
  5,388
  5,947
  6,528
  7,132
  7,760
  8,413
  9,091
  9,798
  10,533
  11,298
  12,095
  12,926
  13,793
  14,697
  15,641
  16,626
  17,656
  18,733
  19,858
  21,035
  22,266
  23,555
  24,905
Total liabilities, $m
  3,631
  4,030
  4,449
  4,887
  5,346
  5,823
  6,321
  6,838
  7,377
  7,936
  8,517
  9,121
  9,749
  10,402
  11,080
  11,787
  12,522
  13,287
  14,084
  14,915
  15,782
  16,686
  17,630
  18,615
  19,645
  20,722
  21,847
  23,024
  24,255
  25,544
  26,894
Total equity, $m
  1,675
  855
  944
  1,037
  1,134
  1,235
  1,341
  1,451
  1,565
  1,683
  1,807
  1,935
  2,068
  2,206
  2,350
  2,500
  2,656
  2,818
  2,988
  3,164
  3,348
  3,539
  3,740
  3,949
  4,167
  4,395
  4,634
  4,884
  5,145
  5,419
  5,705
Total liabilities and equity, $m
  5,306
  4,885
  5,393
  5,924
  6,480
  7,058
  7,662
  8,289
  8,942
  9,619
  10,324
  11,056
  11,817
  12,608
  13,430
  14,287
  15,178
  16,105
  17,072
  18,079
  19,130
  20,225
  21,370
  22,564
  23,812
  25,117
  26,481
  27,908
  29,400
  30,963
  32,599
Debt-to-equity ratio
  0.980
  2.390
  2.610
  2.800
  2.960
  3.100
  3.230
  3.340
  3.440
  3.530
  3.610
  3.690
  3.750
  3.810
  3.870
  3.920
  3.970
  4.010
  4.050
  4.090
  4.120
  4.150
  4.180
  4.210
  4.240
  4.260
  4.290
  4.310
  4.330
  4.350
  4.370
Adjusted equity ratio
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175
  0.175

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  531
  317
  354
  392
  433
  474
  518
  563
  610
  659
  710
  855
  910
  967
  1,026
  1,088
  1,152
  1,219
  1,289
  1,361
  1,437
  1,516
  1,599
  1,685
  1,775
  1,869
  1,968
  2,071
  2,179
  2,292
  2,410
Depreciation, amort., depletion, $m
  213
  257
  271
  285
  300
  315
  331
  348
  366
  384
  403
  296
  316
  338
  360
  383
  406
  431
  457
  484
  512
  542
  572
  604
  638
  673
  709
  747
  787
  829
  873
Funds from operations, $m
  91
  574
  625
  677
  732
  789
  849
  911
  976
  1,043
  1,112
  1,151
  1,226
  1,304
  1,386
  1,470
  1,558
  1,650
  1,746
  1,845
  1,949
  2,058
  2,171
  2,289
  2,413
  2,542
  2,677
  2,818
  2,966
  3,121
  3,283
Change in working capital, $m
  -456
  33
  35
  36
  38
  40
  41
  43
  45
  46
  48
  50
  52
  54
  56
  59
  61
  63
  66
  69
  72
  75
  78
  82
  85
  89
  93
  98
  102
  107
  112
Cash from operations, $m
  547
  545
  590
  641
  694
  750
  808
  868
  931
  996
  1,064
  1,101
  1,174
  1,250
  1,329
  1,412
  1,497
  1,587
  1,680
  1,777
  1,878
  1,983
  2,093
  2,208
  2,328
  2,453
  2,584
  2,721
  2,864
  3,014
  3,171
Maintenance CAPEX, $m
  0
  -118
  -131
  -144
  -159
  -174
  -189
  -205
  -222
  -239
  -258
  -276
  -296
  -316
  -338
  -360
  -383
  -406
  -431
  -457
  -484
  -512
  -542
  -572
  -604
  -638
  -673
  -709
  -747
  -787
  -829
New CAPEX, $m
  -101
  -166
  -173
  -181
  -189
  -197
  -205
  -213
  -222
  -231
  -240
  -249
  -259
  -269
  -280
  -291
  -303
  -316
  -329
  -343
  -357
  -373
  -389
  -406
  -425
  -444
  -464
  -485
  -508
  -531
  -556
Cash from investing activities, $m
  -424
  -284
  -304
  -325
  -348
  -371
  -394
  -418
  -444
  -470
  -498
  -525
  -555
  -585
  -618
  -651
  -686
  -722
  -760
  -800
  -841
  -885
  -931
  -978
  -1,029
  -1,082
  -1,137
  -1,194
  -1,255
  -1,318
  -1,385
Free cash flow, $m
  123
  261
  286
  316
  347
  379
  414
  450
  487
  526
  567
  575
  619
  665
  712
  761
  812
  865
  920
  977
  1,036
  1,098
  1,162
  1,229
  1,299
  1,371
  1,447
  1,526
  1,609
  1,695
  1,786
Issuance/(repayment) of debt, $m
  246
  399
  419
  439
  458
  478
  497
  518
  538
  559
  581
  604
  628
  653
  679
  706
  735
  765
  797
  831
  867
  904
  944
  986
  1,030
  1,076
  1,125
  1,177
  1,232
  1,289
  1,349
Issuance/(repurchase) of shares, $m
  -356
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -75
  399
  419
  439
  458
  478
  497
  518
  538
  559
  581
  604
  628
  653
  679
  706
  735
  765
  797
  831
  867
  904
  944
  986
  1,030
  1,076
  1,125
  1,177
  1,232
  1,289
  1,349
Total cash flow (excl. dividends), $m
  29
  660
  705
  754
  805
  857
  911
  967
  1,025
  1,086
  1,148
  1,179
  1,247
  1,317
  1,391
  1,467
  1,547
  1,630
  1,717
  1,808
  1,903
  2,002
  2,106
  2,215
  2,329
  2,448
  2,573
  2,703
  2,841
  2,984
  3,135
Retained Cash Flow (-), $m
  -220
  -85
  -89
  -93
  -97
  -101
  -106
  -110
  -114
  -119
  -123
  -128
  -133
  -138
  -144
  -150
  -156
  -162
  -169
  -176
  -184
  -192
  -200
  -209
  -218
  -228
  -239
  -250
  -261
  -273
  -286
Prev. year cash balance distribution, $m
 
  905
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  1,480
  616
  661
  708
  756
  806
  857
  911
  967
  1,025
  1,051
  1,114
  1,179
  1,247
  1,317
  1,391
  1,468
  1,548
  1,632
  1,719
  1,810
  1,906
  2,006
  2,110
  2,219
  2,334
  2,454
  2,579
  2,711
  2,849
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  1,419
  564
  575
  583
  586
  585
  579
  570
  555
  537
  499
  475
  448
  419
  387
  353
  319
  285
  251
  218
  187
  158
  131
  107
  86
  68
  53
  40
  30
  21
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. In addition, the company offers oncology products, such as specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Further, it provides surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs; and hemostats and surgical sealants, as well as irrigation, wound drainage, and original equipment manufacturersÂ’ products. The company sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

FINANCIAL RATIOS  of  C.R. Bard (BCR)

Valuation Ratios
P/E Ratio 43.4
Price to Sales 6.2
Price to Book 13.8
Price to Tangible Book
Price to Cash Flow 42.1
Price to Free Cash Flow 51.6
Growth Rates
Sales Growth Rate 8.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -2.9%
Cap. Spend. - 3 Yr. Gr. Rate -0.4%
Financial Strength
Quick Ratio NaN
Current Ratio 0.4
LT Debt to Equity 98%
Total Debt to Equity 98%
Interest Coverage 14
Management Effectiveness
Return On Assets 11.3%
Ret/ On Assets - 3 Yr. Avg. 6.9%
Return On Total Capital 17.2%
Ret/ On T. Cap. - 3 Yr. Avg. 10.1%
Return On Equity 33.9%
Return On Equity - 3 Yr. Avg. 19.1%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 62.9%
Gross Margin - 3 Yr. Avg. 62.3%
EBITDA Margin 25%
EBITDA Margin - 3 Yr. Avg. 20.7%
Operating Margin 19%
Oper. Margin - 3 Yr. Avg. 15.1%
Pre-Tax Margin 17.9%
Pre-Tax Margin - 3 Yr. Avg. 13.8%
Net Profit Margin 14.3%
Net Profit Margin - 3 Yr. Avg. 9%
Effective Tax Rate 20%
Eff/ Tax Rate - 3 Yr. Avg. 38.4%
Payout Ratio 14.1%

BCR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BCR stock intrinsic value calculation we used $3714 million for the last fiscal year's total revenue generated by C.R. Bard. The default revenue input number comes from 2016 income statement of C.R. Bard. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BCR stock valuation model: a) initial revenue growth rate of 11% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BCR is calculated based on our internal credit rating of C.R. Bard, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of C.R. Bard.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BCR stock the variable cost ratio is equal to 88.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BCR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for C.R. Bard.

Corporate tax rate of 27% is the nominal tax rate for C.R. Bard. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BCR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BCR are equal to 40.3%.

Life of production assets of 12.7 years is the average useful life of capital assets used in C.R. Bard operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BCR is equal to 8.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1675 million for C.R. Bard - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 72.326 million for C.R. Bard is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of C.R. Bard at the current share price and the inputted number of shares is $22.9 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
TFX Teleflex 204.35 prem.  prem.
BSX Boston Scienti 27.86 prem.  prem.
MMSI Merit Medical 37.10 prem.  prem.
ANGO AngioDynamics 16.42 prem.  prem.
CRY CryoLife 19.60 prem.  prem.
IART Integra LifeSc 53.81 prem.  prem.
BAX Baxter Interna 60.68 prem.  prem.

COMPANY NEWS

▶ Bard Declares Quarterly Dividend   [Jun-14-17 04:15PM  Business Wire]
▶ Seven iQ100 members hit all-time highs   [03:48PM  CNBC Videos]
▶ Nine members of iQ100 hit all time highs   [Jun-01-17 03:14PM  CNBC Videos]
▶ Albany public company files lawsuit alleging competitor violated antitrust laws   [May-31-17 03:48PM  American City Business Journals]
▶ Seven iQ 100 members hit all-time highs   [01:59PM  CNBC Videos]
▶ Five CNBC IQ 100 components are hitting lifetime highs   [Apr-28-17 12:40PM  CNBC Videos]
▶ 3 Best Performing Stocks of April   [09:04AM  Motley Fool]
▶ Which Companies Are Now Outperforming 95% Of All Stocks?   [11:13AM  Investor's Business Daily]
▶ C. R. Bard Stock Trades Ex-Dividend Thursday   [Apr-25-17 01:10PM  Investopedia]
▶ [$$] Dont Succumb to Sticker Shock on Becton Dickinson Deal   [12:36AM  The Wall Street Journal]
▶ Tax cuts not driving this rally   [Apr-24-17 06:44PM  CNBC Videos]
▶ Story Stocks from Briefing.com   [12:03PM  Briefing.com]
▶ A $24 Billion Megadeal to Cheer About   [09:19AM  Bloomberg]
▶ C.R. Bard tops Street 1Q forecasts   [05:01AM  Associated Press]
▶ Becton Dickinson to Acquire C.R. Bard for $24 Billion   [12:01AM  The Wall Street Journal]
▶ Becton Dickinson to Buy C.R. Bard for $24 Billion   [07:47PM  The Wall Street Journal]
▶ Bard Announces First Quarter Results   [05:07PM  Business Wire]
▶ BD To Acquire Bard For $24 Billion   [05:04PM  PR Newswire]
▶ Bard Declares Quarterly Dividend   [Apr-19-17 04:15PM  Business Wire]
▶ C.R. Bard Just Keeps Going and Going...   [Apr-10-17 02:28PM  TheStreet.com]
▶ Bard to Host Earnings Conference Call on April 26, 2017   [Apr-03-17 12:15PM  Business Wire]
▶ New highs for the CNBC IQ 100   [Mar-13-17 11:48AM  CNBC Videos]
▶ Bard to Present at Barclays Global Healthcare Conference   [Mar-07-17 10:30AM  Business Wire]
▶ Go With the Upside on C.R. Bard   [Feb-27-17 03:29PM  TheStreet.com]
▶ Bard Announces Fourth Quarter Results   [04:15PM  Business Wire]
Stock chart of BCR Financial statements of BCR Annual reports of BCR
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.